I'm LongbridgeAI, I can summarize articles.Everest Medicines secures a massive licensing pact, Sunmi takes IoT to space, and Anta Sports flexes its consumer muscle amidst a rough patch for heavy industrials.
The market is undergoing a notable recalibration, and the divergence is hard to ignore. While legacy heavy industries are taking a hit, biotech pipelines and next-generation hardware are locking in serious momentum.
The big story: Everest Medicines (1952.HK) is making serious waves on the deal front. In July 2026, the company officially closed an exclusive licensing agreement for its renal drug, pulling in USD 112.5 million upfront with the potential to rake in up to USD 1.03 billion in milestone and royalty payments. And that is not all—their cholesterol-lowering biological drug, Lerodalcibep, just had its new drug application accepted by the NMPA in late June. It is a massive expansion for their commercial portfolio.
On the hardware side, Sunmi (6810.HK) continues its push beyond traditional retail point-of-sale systems. In June 2026, the company rolled out a commercial satellite IoT solution tapping into SpaceX's network, aggressively targeting emerging markets where ground infrastructure is scarce.
Meanwhile, consumer and precision manufacturing giants are proving their resilience. Anta Sports (2020.HK) just posted an impressive RMB 80.2 billion in 2025 revenue, driven by strong margin expansions across its FILA segment. In the automotive sector, Zhaowei Machinery (2692.HK) is moving fast to integrate its micro-drive systems into the booming smart cabin ecosystem.
Also in the mix:
- Zheshang Bank (2016.HK): The bank is undergoing a structural governance shift, officially abolishing its supervisory board after receiving regulatory approval in June 2026.
- BII Railway Transportation Tech (1522.HK): The smart rail infrastructure provider continues to quietly expand its footprint, now operating across 65 Chinese cities and 32 overseas markets.
- Jinma Energy (6885.HK): A tough stretch for the coking coal producer. The company reported an expanded net loss of RMB 527 million for 2025, halting its final dividend as gross margins shrank significantly.
- Honghua Group (0196.HK): The state-backed drilling equipment manufacturer is pivoting hard, leveraging its Qidong base to grab a larger slice of the offshore oil and gas equipment market.
- E Fund Gold ETF (2824.HK): For investors tracking the underlying mining momentum amidst ongoing market volatility, this ETF remains the primary vehicle of choice.
- Zhenjiankang Medical (2697.HK): The medical tech outfit continues to steadily build out its operational footprint in the background.